Abstract
Background: Malignant ascites is a major problem in the management of advanced stages of certain malignancies. The possibility of reducing the accumulation of ascites by intraperitoneal injections of a Viscum album extract (Iscador M®) was evaluated. Patients and Methods: Twenty-three patients, with end-stage malignancies of varying histology, requiring repeated peritoneal punctures, were eligible for analysis. The time-interval between the first two punctures was measured and defined as the baseline. Following each subsequent puncture, Iscador M® 10 mg was injected intraperitoneally. The intervals between later punctures were compared to previous intervals. Results: Following the first injection, the median time-interval between injections increased from 7 to 12 days, reaching 13 days after the second injection. No toxicity was observed. Conclusion: This phase II study suggests that installation of Iscador M® into the peritoneal cavity may reduce the need for repeated punctures. A randomized trial is needed to confirm these promising preliminary results.
Original language | English |
---|---|
Pages (from-to) | 709-713 |
Number of pages | 5 |
Journal | Anticancer Research |
Volume | 26 |
Issue number | 1 B |
State | Published - Jan 2006 |
Externally published | Yes |
Keywords
- Iscador M®
- Malignant ascites
- Viscum album